OMDA
Omada Health, Inc.
Next earnings Aug 5, 2026 · consensus $0.01 EPS, $81.8M rev
Last earnings +3.4% on 2026-05-07
$20.89
▲ +10.53%$20.89▲ +40.67%
over 1Y
L $10.94EODHDH $26.78
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+10.5%
1W+16.2%
1M+26.9%
3M+76.2%
YTD+40.2%
1Y+40.7%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 18 analysts
Buy
Revenue grew 53.2% YoY; but unprofitable (net margin -4.9%).
Revenue (FY2025) $260M · FY2025
Omada Health, Inc. shows $260M in FY2025 revenue (+53.2% YoY), a -4.9% net margin, and -5.6% ROE.
Financials · annual, by fiscal year
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | $123M | $170M | $260M |
| Gross profit | $70.0M | $103M | $171M |
| Operating income | -$66.0M | -$43.7M | -$12.0M |
| Net income | -$67.5M | -$47.1M | -$12.8M |
| Diluted EPS | -$9.52 | -$6.11 | -$0.35 |
| Net margin | -55.0% | -27.8% | -4.9% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$1.01B
EV / EBITDA—
EV / Sales3.9
EV / FCF59.6
P / FCF72.7
PEG (trailing)—
Earnings yield-1.0%
FCF yield1.4%
Quality & risk
ROIC (est.)-4.1%
Free cash flow$16.9M
Total debt$0.00
Net cash$222M
Altman Z-Score9.16 safe
Piotroski F-Score6/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗4Period ending 2026-06-242026-06-26open ↗4Period ending 2026-06-242026-06-26open ↗4Period ending 2026-06-242026-06-26open ↗144Filing2026-06-26open ↗144Filing2026-06-26open ↗144Filing2026-06-26open ↗144Filing2026-06-25open ↗144Filing2026-06-25open ↗4/APeriod ending 2026-06-122026-06-24open ↗144Filing2026-06-24open ↗144Filing2026-06-24open ↗144Filing2026-06-24open ↗
Frequently asked
- Is Omada Health, Inc. (OMDA) a buy?
- OMDA currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 53.2% YoY; but unprofitable (net margin -4.9%).
- What is Omada Health, Inc.'s quality score?
- OMDA scores 56.80392156862745/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001611115, latest 10-Q filed 2026-05-08) · EODHD · as of 6/23/2026, 1:57:30 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.